Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integra Lifesciences HoldingsIART -0.33%70 Days Sales Outstanding is 57.92 as of Jun. 2026, which is 6% below its 10-year median of 61.48. GuruFocus rates IART with a GF Score™ of 70/100 and a GF Value™ of $20.52 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 810 Medical Devices & Instruments companies, Integra Lifesciences Holdings ranks better than 56.67% on this metric.
The historical rank and industry rank for Integra Lifesciences Holdings's Days Sales Outstanding or its related term are showing as below:
IART'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 51.59 Med: 61.48 Max: 66.63
Current: 60.13
During the past 13 years, Integra Lifesciences Holdings's highest Days Sales Outstanding was 66.63. The lowest was 51.59. And the median was 61.48.
IART's Days Sales Outstanding is ranked better than 56.67% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.03
vs IART: 60.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings Days Sales Outstanding Chart
IART vs ENOV, AHCO, INSP: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Integra Lifesciences Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integra Lifesciences Holdings Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Integra Lifesciences Holdings's Days Sales Outstanding falls into.
Integra Lifesciences Holdings Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integra Lifesciences Holdings (IART) has a Days Sales Outstanding of 57.92 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Integra Lifesciences Holdings and its competitors. This is near median its historical median of 61.48. Over the past decade, Integra Lifesciences Holdings' Days Sales Outstanding has ranged from 51.59 to 66.63. According to the industry distribution chart, Integra Lifesciences Holdings ranks #351 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 43.3%.
Is Integra Lifesciences Holdings' Days Sales Outstanding too high?
Integra Lifesciences Holdings' current Days Sales Outstanding of 57.92 is near median its 10-year median of 61.48. Over the past 10 years, this metric has ranged from a low of 51.59 to a high of 66.63. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.03. Integra Lifesciences Holdings' value of 57.92 is 10.9% below this industry median. Based on the distribution chart, Integra Lifesciences Holdings ranks #351 out of 810 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Days Sales Outstanding compare to ENOV and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Integra Lifesciences Holdings ranks #351 out of 810 companies for Days Sales Outstanding. This puts Integra Lifesciences Holdings in the upper half of its industry. The industry median Days Sales Outstanding is 65.03. Integra Lifesciences Holdings' value of 57.92 is 10.9% below this benchmark. Historically, Integra Lifesciences Holdings' own Days Sales Outstanding has ranged from 51.59 to 66.63 over the past decade. While the company's 10-year median is 61.48 vs. the industry median of 65.03, Integra Lifesciences Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.03, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integra Lifesciences Holdings's current Days Sales Outstanding of 57.92 is 10.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Integra Lifesciences Holdings and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integra Lifesciences Holdings's current Days Sales Outstanding is 57.92, which is near median its own 10-year median of 61.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.52, compared to a current price of $16.69 — trading 18.7% below its estimated fair value. The current Days Sales Outstanding is 57.92, which is near median its 10-year median of 61.48 and 10.9% below the Medical Devices & Instruments industry median of 65.03. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current Days Sales Outstanding is 57.92 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integra Lifesciences Holdings (IART) Overvalued in 2026?
Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued.
The current stock price of $16.69 is trading 18.7% below its estimated GF Value™ of $20.52.
GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.
Key valuation signals for IART:
Days Sales Outstanding: 57.92 (near median its 10-year median of 61.48)
GF Value™: $20.52 vs. price of $16.69 (18.7% below fair value)
Industry Position: 10.9% below the Medical Devices & Instruments median (#351 of 810)
No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score
Get the complete analysis for IART
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IART has been successfully added to your 
